South Korean firm to launch 'Ozempic face' filler made from donated fat

South Korea's beauty industry is poised for a new trend as biotech firm L&C Bio Co. prepares to introduce an injectable filler designed to combat the "Ozempic face." This condition, characterized by a loss of facial volume, is an emerging concern linked to the widespread use of popular weight-loss medications.

L&C Bio's innovative product is derived from donated human fat, offering a potential solution for individuals experiencing facial thinning due to rapid weight reduction. The company is positioning this as a significant advancement in cosmetic treatments, aiming to meet the growing demand for procedures that address the aesthetic side effects of weight-loss drugs.

As the first South Korean beauty industry company to utilize donated human tissues for skin fillers, L&C Bio anticipates that the surge in demand for cosmetic enhancements will fuel its business growth. The company's strategy hinges on capturing a market segment increasingly focused on maintaining facial aesthetics amidst significant body transformations.

The development highlights a growing intersection between pharmaceutical advancements in weight management and the cosmetic industry's response. The "Ozempic face" phenomenon, while not a formally recognized medical condition, represents a tangible concern for many users of these powerful medications, creating a new niche for aesthetic treatments.